STOCK TITAN

Harmony Biosciences Holdings Inc - HRMY STOCK NEWS

Welcome to our dedicated news page for Harmony Biosciences Holdings (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harmony Biosciences Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harmony Biosciences Holdings's position in the market.

Rhea-AI Summary
Harmony Biosciences completes acquisition of Zynerba Pharmaceuticals, expanding its portfolio with Zygel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
-
Rhea-AI Summary
Harmony Biosciences presents new data on pitolisant for the treatment of excessive daytime sleepiness in Prader-Willi syndrome
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. extends tender offer for Zynerba Pharmaceuticals, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
Rhea-AI Summary
Jeffrey M. Dayno, CEO of Harmony Biosciences, named to the 2023 PharmaVoice 100 list for his commitment to rare neurological diseases. Harmony Biosciences focuses on innovative therapies for these patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. to participate in fireside chat at 2023 Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
conferences
-
Rhea-AI Summary
Harmony Biosciences receives FDA's Orphan Drug designation for pitolisant in the treatment of idiopathic hypersomnia (IH)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. receives favorable decision from USPTO on WAKIX patent, reinforcing confidence in the product's potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
none
-
Rhea-AI Summary
Harmony Biosciences announces agreement to acquire Zynerba Pharmaceuticals for $60 million in cash, with potential additional payments of up to $140 million based on milestones. Acquisition aims to develop treatment for Fragile X syndrome and other rare neuropsychiatric disorders. Zygel, Zynerba's lead asset, is currently being evaluated in a pivotal Phase 3 clinical trial for FXS. Transaction expected to close by Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. reported net revenue of $134.2 million for Q2 2023, a 25% increase YoY. The average number of patients on WAKIX increased by 350 sequentially to 5,450. The company completed enrollment in the Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study and plans to initiate a Phase 3 study for Prader-Willi Syndrome (PWS) in Q4 2023. The Board of Directors authorized a $125 million share repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
buyback
Harmony Biosciences Holdings Inc

Nasdaq:HRMY

HRMY Rankings

HRMY Stock Data

1.68B
34.79M
19.38%
90.04%
11.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Plymouth Meeting

About HRMY

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.